

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 November 2003 (20.11.2003)

PCT

(10) International Publication Number
WO 03/094915 A1

(51) International Patent Classification⁷: **A61K 31/41**,
A61P 7/02

WEBB, Randy, Lee [US/US]; 17 Honeyman Drive,
Flemington, NJ 08822 (US).

(21) International Application Number: PCT/EP03/04997

(74) Agent: **GROS, Florent**; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(22) International Filing Date: 13 May 2003 (13.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/380,373 14 May 2002 (14.05.2002) US
60/395,014 11 July 2002 (11.07.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for all designated States except AT, US*): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basle (CH).

(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Wien (AT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MALININ, Alex** [RU/US]; 9 Windy Cliff Place, Apt. H., Cockeysville, MD 21030 (US). **SEREBRUANY, Victor, L.** [US/US]; 9101 East Stayman Drive, Ellicott City, MD 21042 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF VALSARTAN OT ITS METABOLITE TO INHIBIT PLATELET AGGREGATION

(57) Abstract: The invention relates to a method of inhibiting platelet aggregation comprising administering a therapeutically effective amount of an ARB or its metabolite, especially Valsartan or its metabolite valeryl 4-hydroxy valsartan. Conditions to be treated by inhibition of platelet aggregation include acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion.



WO 03/094915 A1

USE OF VALSARTAN OR ITS METABOLITE TO INHIBIT PLATELET AGGREGATION

BACKGROUND OF THE INVENTION

Valsartan selectively blocks the binding of angiotensin II to the A_{T1} receptor causing vasodilatation, and diminishes aldosterone secretion. Recent clinical studies revealed additional benefits of Valsartan in a cohort of patients after acute vascular events. Considering that platelet activation plays a key role in the pathogenesis of coronary and cerebrovascular occlusion, and that A_{T1} receptors are present on the platelet surface the *in vitro* effects of Valsartan and its major liver metabolite, valeryl 4-hydroxy valsartan on platelets in subjects with multiple risk factors for vascular disease was assessed.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings depict certain embodiments of the invention. They are illustrative only and do not limit the invention otherwise disclosed herein.

Figure 1 A-C. Actual scanned platelet aggregation curves from a study patient at baseline (A), and after incubation with 100 μ M of valsartan (B), and 1 μ M of VALERYL 4-HYDROXY VALSARTAN (C). High concentrations of valsartan significantly inhibit ADP - induced aggregation (B), with no effect on epinephrine - induced aggregability, while the metabolite blocks epinephrine - induced aggregation (C) in the therapeutic concentration range.

SUMMARY OF THE INVENTION

In one aspect the present invention relates to a method of inhibiting platelet aggregation comprising administering a therapeutically effective amount of an angiotensin II receptor blocker ("ARB"), preferably valsartan, or pharmaceutically acceptable salts thereof, optionally in the presence of a pharmaceutically acceptable carrier, to a patient in need thereof.

In another embodiment the present invention relates to a method of inhibiting platelet aggregation comprising administering a therapeutically effective amount of a metabolite of an ARB, especially the metabolite of Valsartan, valeryl 4-hydroxy valsartan, optionally in the presence of a pharmaceutically acceptable carrier, to a patient in need thereof.


In another aspect of the present invention there is provided a method of treating conditions associated with platelet aggregation comprising administering an ARB or a metabolite of an ARB to a patient in need thereof. Conditions associated with platelet aggregation include acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion.

Another aspect of the present invention relates to pharmaceutical compositions comprising an ARB or a metabolite of an ARB and a pharmaceutically acceptable carrier.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS


AT₁-receptor antagonists (also called angiotensin II receptor antagonists) are understood to be those active ingredients which bind to the AT₁-receptor subtype of angiotensin II receptor but do not result in activation of the receptor. As a consequence of the inhibition of the AT₁ receptor, these antagonists can, for example, be employed as to prevent platelet aggregation and treat conditions associated therewith.

The class of AT₁ receptor antagonists comprises compounds having differing structural features, essentially preferred are the non-peptidic ones. The ARBs within the scope of the present invention include valsartan, which is the AT₁ receptor antagonist (S) –N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2;(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine of formula (I)




and is disclosed in EP 0443983 A and United States Patent 5,399,578, the disclosures of which are incorporated herein in their entirety as if set forth herein. Other ARB compounds include, but are not limited to, losartan, candesartan, eprosartan, irbesartan, saprisartan, tasosartan, telmisartan, olmesartan, zolarsartan (1-[[3-bromo-2-[2-(1H-tetrazol-5-yl)phenyl]-5-benzofuranyl]methyl]-2-butyl-4-chloro-1H-imidazole-5-carboxylic acid, and 3-(3-Bromo-2-[2-(1H-tetrazol-5-yl)-phenyl]-bezofuran-5-yl methyl)-2-butyl-5-chloro-3H-imidazole-4-carboxylic acid, methyl 2-[[4-butyl-2-methyl-6-oxo-5-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1(6H)-pyrimidinyl]methyl]-3-thiophenecarboxylate also known as LR-B/081 and Methyl 2-[[4-butyl-2-methyl-6-oxo-5-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-(6H)-pyrimidinyl]methyl]-3-thiophenecarboxylate also known as 3k, LR-B/081 which has the introduction of a (carboxyheteroaryl)methyl moiety at the 3-position (Lusofarmaco), 2,7-diethyl-5-[[2'-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl]-5H-pyrazolo[1,5-b][1,2,4]-triazole potassium salt also known as YM 358 (Yamanouchi) disclosed in Biol Pharm Bull 2000 Feb;23(2):174-81, L-158,809 disclosed in Thromb Res 2002 Mar 15;105(6):531-6, KT3 671 disclosed in J Cardiovasc Pharmacol 1995 Jan;25(1):22-9, TA 606 disclosed in J Cardiovasc Pharmacol 1998 Apr;31(4):568-75, TH 142177 disclosed in Fundam Clin Pharmacol 1997;11(5):395-401, UP


269-6 disclosed in Br J Pharmacol 1997 Feb;120(3):488-94, the compound with the designation E-1477 of the following formula



the compound with the designation SC-52458 of the following formula



and the compound with the designation the compound ZD-8731 of the following formula



or, in each case, a pharmaceutically acceptable salt thereof.

It has also been surprisingly found that metabolites of ARBs also significantly reduce platelet aggregation. Metabolites of ARBs include

metabolite of losartan, which is, 2-n-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)-biphenyl-4-yl)methyl]imidazole-5-carboxylic acid hydrochloride also called EXP-3174 as disclosed in J Pharmacol Exp Ther 1990 Oct;255(1):211-7 and the metabolite EXP-3174 (II) disclosed in J Chromatogr 1992 Jan 17;573(2):295-301;

metabolites of irbesartan, which are 1) a tetrazole N2-beta-glucuronide conjugate of irbesartan, (2) a monohydroxylated metabolite resulting from omega-1 oxidation of the butyl side chain, (3, 4) two different monohydroxylated metabolites resulting from oxidation of the spirocyclopentane ring, (5) a diol resulting from omega-1 oxidation of the butyl side chain and oxidation of the spirocyclopentane ring, (6) a keto metabolite resulting from further oxidation of the omega-1 monohydroxy metabolite, (7) a keto-alcohol resulting from further oxidation of the omega-1 hydroxyl of the diol, and (8) a carboxylic acid metabolite resulting from oxidation of the terminal methyl group of the butyl side chain disclosed in Drug Metab Dispos 1998 May;26(5):408-17;

metabolite of candesartan cilexetil, which is candesartan (2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid), also known as CV 11974 and CV-15959 disclosed in Clin Pharmacokinet 2002;41(1):7-17, J Chromatogr B Biomed Sci Appl 1999 Aug 20;731(2):411-7, and J Hum Hypertens 1997 Sep;11 Suppl 2:S19-25;

metabolite of telmisartan, which is telmisartan 1-O-acylglucuronide disclosed in Drug Metab Dispos 1999 Oct;27(10):1143-9;

metabolite of olmesartan medoxomil, which is olmesartan or CS866, as disclosed in J Hypertens Suppl 2001 Jun;19 Suppl 1:S21-32 ;


metabolite of eprosartan, which is glucuronide disclosed in Pharmacotherapy 1999 Apr;19(4 Pt 2):73S-78S;

metabolite of tasosartan, which is enoltasosartan disclosed in J Pharmacol Exp Ther 2000 Nov;295(2):649-54 and five other metabolites disclosed in J. Med. Chem. 1998, Oct. 22, 41(22), 4251-60;

metabolite of zolarsartan, which is glucuronic acid conjugates and five related to biotransformation products, three hydroxylated on the aliphatic side chain, one further oxidized

to a ketone and one hydroxylated on the phenyl ring disclosed in J Pharm Biomed Anal 1994 Sep;12(9):1181-7 and J Pharm Biomed Anal 1994 Sep;12(9):1181-7;
 metabolite of ZD-8731;
 metabolite of (5-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl) methyl]-2-[2-(1H-tetrazol-5-ylphenyl)]pyridine also known as SC-52458 disclosed in J Cardiovasc Pharmacol 1993 Oct;22(4):617-25;
 and metabolites of the following ARBs, ZD-8731 (Zeneca), methyl 2-[[4-butyl-2-methyl- 6-oxo-5-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1(6H)- pyrimidinyl]methyl]-3-thiophenecarboxylate also known as LR-B/081 and Methyl 2-[[4-butyl-2-methyl-6-oxo-5-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-(6H)-pyrimidinyl]methyl]-3-thiophenecarboxylate also known as 3k, LR-B/081 which has the introduction of a (carboxyheteroaryl)methyl moiety at the 3-position (Lusofarmaco), 2,7-diethyl-5-[[2'-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl]-5H-pyrazolo[1,5-b][1,2,4]-triazole potassium salt also known as YM 358 (Yamanouchi) disclosed in Biol Pharm Bull 2000 Feb;23(2):174-81, L-158,809 disclosed in Thromb Res 2002 Mar 15;105(6):531-6, KT3 671 disclosed in J Cardiovasc Pharmacol 1995 Jan;25(1):22-9, TA 606 disclosed in J Cardiovasc Pharmacol 1998 Apr;31(4):568-75, TH 142177 disclosed in Fundam Clin Pharmacol 1997;11(5):395-401 and UP 269-6 disclosed in Br J Pharmacol 1997 Feb;120(3):488-94.

Preferred is the metabolite of Valsartan which is valeryl 4-hydroxy valsartan having the formula



, disclosed in Waldmeier F., et al.,

Xenobiotica, 1997, Vol. 27, No. 1, 59-71, hereby incorporated by reference in its entirety as if set forth in full herein.

ARBs and their metabolites may be referred to herein as "the compounds of the invention". The compounds of the invention depending on the nature of the substituents, may possess one or more asymmetric centers. The resulting diastereoisomers, enantiomers and geometric isomers are encompassed by the instant invention.

Depending on the choice of starting materials and methods, the compounds may be in the form of one of the possible isomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, optical isomers (antipodes), racemates, or mixtures thereof. The aforesaid possible isomers or mixtures thereof are within the purview of this invention.

Any resulting mixtures of isomers can be separated on the basis of the physico-chemical differences of the constituents, into the pure geometric or optical isomers, diastereoisomers, racemates, for example by chromatography and/or fractional crystallization.

Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g. by separation of the diastereoisomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. The carboxylic acid intermediates can thus be resolved into their optical antipodes e.g. by fractional crystallization of D- or L-(alpha-methylbenzylamine, cinchonidine, cinchonine, quinine, quinidine, ephedrine, dehydroabietylamine, brucine or strychnine)-salts. Racemic products can also be resolved by chiral chromatography, e.g. high pressure liquid chromatography using a chiral adsorbent.

Finally, compounds of the invention are either obtained in the free form, or as a salt thereof if salt forming groups are present.

Acidic compounds of the invention may be converted into salts with pharmaceutically acceptable bases, e.g. an aqueous alkali metal hydroxide, advantageously in the presence of an ethereal or alcoholic solvent, such as a lower alkanol. From the solutions of the latter, the salts may be precipitated with ethers, e.g. diethyl ether. Resulting salts may be converted into the free compounds by treatment with acids. These or other salts can also be used for purification of the compounds obtained.

Compounds of the invention having basic groups can be converted into acid addition salts, especially pharmaceutically acceptable salts. These are formed, for example, with inorganic acids, such as mineral acids, for example sulfuric acid, a phosphoric or hydrohalic acid, or with organic carboxylic acids, such as (C₁-C₄)-alkanecarboxylic acids which, for example, are unsubstituted or substituted by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, succinic, maleic or fumaric acid, such as hydroxy-carboxylic acids, for example glycolic, lactic, malic, tartaric or citric acid, such as amino acids, for example aspartic or glutamic acid, or with organic sulfonic acids, such as (C₁-C₄)-alkyl-sulfonic acids (for example methanesulfonic acid) or arylsulfonic acids which are unsubstituted or substituted (for example by halogen). Preferred are salts formed with hydrochloric acid, methanesulfonic acid and maleic acid.

In view of the close relationship between the free compounds and the compounds in the form of their salts, whenever a compound is referred to in this context, a corresponding salt is also intended, provided such is possible or appropriate under the circumstances.

The compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.

Another aspect of the invention includes pharmaceutical compositions comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. The pharmaceutical compositions according to the invention can be prepared in a manner known per se and are those suitable for enteral, such as oral or rectal, and parenteral administration to mammals (warm-blooded animals), including man, comprising a therapeutically effective amount of the pharmacologically active compound, alone or in combination with one or more pharmaceutically acceptable carriers, especially suitable for enteral or parenteral application. Typical oral formulations include tablets, capsules, syrups, elixirs and suspensions. Typical injectable formulations include solutions and suspensions. The pharmaceutical compositions may be employed for the treatment of conditions mediated by platelet aggregation, in particular, acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular

syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion.

The typical pharmaceutically acceptable carriers for use in the formulations described above are exemplified by: sugars such as lactose, sucrose, mannitol and sorbitol; starches such as cornstarch, tapioca starch and potato starch; cellulose and derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and methyl cellulose; calcium phosphates such as dicalcium phosphate and tricalcium phosphate; sodium sulfate; calcium sulfate; polyvinylpyrrolidone; polyvinyl alcohol; stearic acid; alkaline earth metal stearates such as magnesium stearate and calcium stearate; stearic acid; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil and corn oil; non-ionic, cationic and anionic surfactants; ethylene glycol polymers; betacyclodextrin; fatty alcohols; and hydrolyzed cereal solids, as well as other non-toxic compatible fillers, binders, disintegrants, buffers, preservatives, antioxidants, lubricants, flavoring agents, and the like commonly used in pharmaceutical formulations.

These pharmaceutical preparations are for enteral, such as oral, and also rectal or parenteral, administration to homeotherms, with the preparations comprising the pharmacological active compound either alone or together with customary pharmaceutical auxiliary substances. For example, the pharmaceutical preparations consist of from about 0.1 % to 90 %, preferably of from about 1 % to about 80 %, of the active compounds. Pharmaceutical preparations for enteral or parenteral administration are, for example, in unit dose forms, such as coated tablets, tablets, capsules or suppositories and also ampoules. These are prepared in a manner which is known per se, for example using conventional mixing, granulation, coating, solubilizing or lyophilizing processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, if desired granulating a mixture which has been obtained, and, if required or necessary, processing the mixture or granulate into tablets or coated tablet cores after having added suitable auxiliary substances.

ARBs, especially valsartan, and metabolites of ARBs, especially valeryl 4-hydroxy valsartan, may be combined with other therapeutic agents, e.g., each at an effective therapeutic dose as reported in the art. Such therapeutic agents include heparin, warfarin, t-PA, urokinase,

streptokinase, aspirin, ticlopidine, clopidogrel, abciximab, eptifibatide and tirofiban, anti-hypertensive agents and anti-diabetics.

The dosage of the active compound can depend on a variety of factors, such as mode of administration, homeothermic species, age and/or individual condition.

Preferred dosages for the active ingredients according to the present invention are therapeutically effective dosages, especially those which are commercially available for valsartan.

Normally, in the case of oral administration of the compounds of the present invention, an approximate daily dose of from about 0.1 mg to about 360 mg is to be estimated e.g. for a patient of approximately 75 kg in weight.

Valsartan is supplied in the form of suitable dosage unit form, for example, a capsule or tablet, and comprising a therapeutically effective amount, e.g. from about 20 to about 320 mg, of valsartan which may be applied to patients. The application of the active ingredient may occur up to three times a day, starting e.g. with a daily dose of 20 mg or 40 mg of valsartan, increasing to 80 mg daily and further to 160 mg daily up to 320 mg daily. Preferably, valsartan is applied once a day or twice a day to patients with a dose of 80 mg or 160 mg, respectively, each. Corresponding doses may be taken, for example, in the morning, at mid-day or in the evening.

In case of valeryl 4-hydroxy valsartan, preferred dosage unit forms are, for example, tablets or capsules comprising e.g. for a mammal of about 50 to 70 kg from about 1 mg to about 1000 mg, advantageously from about 5 mg to about 500 mg, even more advantageously from about 20 mg to about 320 mg, administered once a day.

The above doses encompass a therapeutically effective amount of the active ingredients of the present invention.

It has surprisingly been found that both ARBs, particularly valsartan and the metabolites of ARBs, particularly valeryl 4-hydroxy valsartan exhibit significant *in vitro* inhibition of human platelets.

The compounds of the present invention inhibit platelet aggregation, and thus may be employed for the treatment of conditions mediated by platelet aggregation, in particular, acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of

ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion.

The invention furthermore also relates to a compound according to the invention for use in the prevention of, delay of progression of, treatment of a disease or condition mediated by platelet aggregation, in particular, acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion.

The invention furthermore also relates to the use of a compound according to the invention for the manufacture of a medicament for the prevention, delay of progression or treatment of a disease and disorder mediated by platelet aggregation, in particular, acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion.

The above-cited properties have been demonstrated by the following method: Blood samples for platelet aggregation, flow cytometric studies, and cartridge-based platelet assay analyzers were obtained from 20 volunteers with known vascular risk factors. Study participants were excluded if they had a history of bleeding diathesis, history of stroke, major surgery or significant trauma in the past six months, and hypertension of more than 200/110 mm. None of them received aspirin or any other anti-platelet agents. All subjects underwent blood sampling after at least 30 minutes of rest and 2 or more hours of fasting. Blood was drawn between 8 and 10 a.m. in order to avoid any diurnal influence and sampled from an

antecubital vein using a 21-gauge butterfly needle containing 3.8% sodium citrate (1:9 volume) after having discarded the first 1.5 ml of free running blood. Eleven Vacutainer tubes (4.5 ml) were collected for a total of 49 ml of whole blood - citrate mixture from each study participant. One tube was kept as an internal control and was incubated with buffer solution. Five tubes were incubated with valsartan for 60 minutes at 37°C in order to achieve the final concentrations of the compound at 10nM, 100nM, 1µM, 10µM, and 100µM. The remaining five tubes were similarly incubated with increasing amounts of valeryl 4-hydroxy valsartan to achieve concentrations of 10nM, 100nM, 1µM, 10µM, and 100µM. The concentrations of valsartan and valeryl 4-hydroxy valsartan ranged from subtherapeutic to markedly supra-therapeutic plasma levels observed in patients undergoing valsartan therapy. Valsartan peak plasma concentration can reach as high as 7.5µM after a 160mg intake, while valeryl 4-hydroxy valsartan in plasma represents only 10% of valsartan levels. Fresh solutions of valsartan and valeryl 4-hydroxy valsartan were prepared ex tempore on the same morning the platelet studies were performed. To avoid possible observer bias, blood samples were coded and blinded. Sampling procedures, and platelet studies were performed by individuals unaware of the protocol.

Platelet aggregation

A. Platelet -rich plasma

The citrate and whole blood mixture were centrifuged at 1200g for 5 minutes in order to obtain platelet- rich plasma (PRP) which was kept at room temperature for use within 1 hour. Platelet counts were determined for each PRP sample with a Coulter Counter ZM (Coulter Co., Hialeah, FL). Platelet numbers were adjusted to 3.50×10^8 /ml with homologous platelet-poor plasma. Platelet aggregation (PA) was induced by 5 µM ADP, and 5 µM epinephrine. All agonists were obtained from Chronolog Corporation (Havertown, PA). Aggregation studies were performed using a 4 channel Chronolog Lumi-Aggregometer (model 560 - Ca). Aggregation was expressed as the maximum percentage of light transmittance change (% max) from the baseline at the end of the recording time, using platelet-poor plasma as a reference. Aggregation curves were recorded for 6 minutes and analyzed according to internationally established standards. Ruggeri ZM, Semin Hemat 1994; 31: 229 - 239.

B. Whole blood

The methods are described in detail in Abbate R, et al., *Amer J Clin Pathol* 1986; 86: 91-96. Briefly, the whole blood citrate mixture was diluted 1:1 with 0.5 ml TBS, then swirled gently. The cuvette with the stirring bar was placed in the incubation well and allowed to warm to 37°C for 5 minutes. Then the sample was transferred to the assay well. An electrode was placed in the sample cuvette. Platelet aggregation was stimulated with 1 µg/ml collagen. Platelet aggregation studies were performed using a Chrono-Log Whole Blood Aggregometer using Aggrolink" software. Platelet aggregability was expressed as the change in electrical impedance and is expressed in ohms.

Whole Blood Flow Cytometry

The expression of platelet receptors was determined by using the following monoclonal antibodies: CD31 (platelet endothelial cell adhesion molecule (PECAM-1), CD41 (glycoprotein [GP] IIb/IIIa, (IIb (3), CD42b (GP Ib), CD 51/CD61 ((v (3, or vitronectin receptor), CD62p (P-selectin), CD107a (lysosome associated membrane protein -1; LAMP-1), CD 107b (LAMP-2), CD151 (platelet/endothelial tetraspan antigen -3; PETA-3), and PAC-1 for fibrinogen-platelet (PharMingen, San Diego, CA). Platelet-leukocyte interactions were assessed by using dual antibodies for a pan-platelet marker (CD151), together with CD14, a monocyte/macrophage marker. The blood-citrate mixture (50 µl) was diluted with 450 µl Tris buffered saline (TBS) (10 mmol/L Tris, 0.15 mol/L sodium chloride) and mixed by gently inverting an Eppendorf tube 2 times. Five µl of the corresponding antibodies were then added to each solution and the samples were incubated for 30 minutes. After incubation, 400 µl of 2% buffered paraformaldehyde was added for fixation. The samples were analyzed by a Becton Dickinson FACScan flow cytometer set up to measure fluorescent light scatter, as described in Gurbel PA, et al., *J Am Coll Cardiol.* 1998;31:1466-1473. The data were collected in list mode files and then analyzed. P selectin was expressed as percent positive cells as described in Gurbel PA, et al, *Am Heart J* 2000; 139: 320-328. Other antigens were expressed as log mean fluorescence intensity.

Cartridge-Based Platelet Analyzers

The platelet function analyzer (PFA-100', Dade Behring, Deerfield, IL) is a device that simulates changes in primary hemostasis after injury to a small vessel under flow conditions. Kundu SK, et al., Semin Thromb Hemost 1995;21(Suppl 2):106-112. The time required to obtain occlusion of the aperture was digitally recorded as a measure of shear-induced platelet aggregation. Closure time determinations were performed in duplicate.

A rapid platelet-function assay cartridge test (RPFA-ASA, Ultegra(r) Accumetrics, Inc., San Diego, CA, USA), using polystyrene beads coated cartridges with lyophilized human fibrinogen-coated microparticles, and propyl gallat served as an agonist. The whole blood citrate mixture was added to the cartridge, and agglutination between platelets and coated beads was recorded. The data mirrored turbidometric platelet aggregation and reflected the degree of platelet prostaglandin blockade. Smith JW, et al., Circulation 1999;99:620-625. Ultegra(r) assays were performed in duplicate. An electronic quality control test was performed on each instrument every day of use prior to performing any subject samples.

Statistical Analysis

All comparisons were calculated by Student's t-test to identify specific differences in platelet aggregation, results of Ultegra(r), Dade-PFA 100(tm), and receptor expression between baseline and post valsartan/valeryl 4-hydroxy valsartan incubation. The Mann-Whitney U test was used to analyze non-parametric data. Normally distributed data were expressed as mean $\pm$ SE, and skewed data as median (range). Probability values of $p < 0.05$ were regarded as statistically significant. Linear regression analysis was applied to normally distributed data for all study participants by using the SPSS v9.0 program (SPSS Inc. Chicago, Illinois) for statistical analysis.

Platelet aggregation in platelet-rich plasma

Preincubation with escalating doses of valsartan resulted in inhibition of ADP - induced platelet aggregation only at a concentration of 100 μ M which exceeds the therapeutic level, and did not affect the epinephrine-induced platelet aggregation. In contrast, incubation with valeryl 4-hydroxy valsartan inhibited epinephrine-induced aggregation in concentration 1 μ M and 10 μ M, and did not have any effect on ADP-induced aggregation. Representative data for 5 μ M ADP and 5 μ M epinephrine-stimulated aggregation are shown at Table 1.

Table 1. PRP platelet aggregation

Variable	Valsartan (V)	Valeryl 4-hydroxy valsartan (valeryl 4-hydroxy valsartan)	
Drug concentration	p-value vs. baseline	p-value vs. baseline	p-value V vs. valeryl 4- hydroxy valsartan

Platelet rich plasma aggregation induced by 5 μ M ADP (%)

Baseline	75 $\pm$ 8		75 $\pm$ 8		
10 nM	74 $\pm$ 6	NS	75 $\pm$ 6	NS	NS
100 nM	75 $\pm$ 8	NS	76 $\pm$ 8	NS	NS
1 μ M	76 $\pm$ 7	NS	77 $\pm$ 9	NS	NS
10 μ M	75 $\pm$ 8	NS	76 $\pm$ 8	NS	NS
100 μ M	55 $\pm$ 12	0.0002	77 $\pm$ 9	NS	0.001

Platelet rich plasma platelet aggregation induced by
5 μ M epinephrine (%)

Baseline	78 $\pm$ 10		78 $\pm$ 10		
10 nM	77 $\pm$ 11	NS	77 $\pm$ 10	NS	NS
100 nM	76 $\pm$ 10	NS	76 $\pm$ 9	NS	NS
1 μ M	78 $\pm$ 6	NS	54 $\pm$ 11	0.0001	0.0001
10 μ M	75 $\pm$ 9	NS	56 $\pm$ 13	0.001	0.003
100 μ M	76 $\pm$ 7	NS	52 $\pm$ 9	0.0001	0.0001

Platelet aggregation in whole blood

Valsartan and valeryl 4-hydroxy valsartan inhibited aggregation of human platelets induced by 1 μ M collagen in whole blood within the range of therapeutic activity. A dose

dependent effect was observed for the both of compound, but preincubation with valeryl 4-hydroxy valsartan resulted in a significant reduction of platelet aggregability. The results of collagen - induced platelet aggregation are demonstrated by Table 2.

Table 2. Whole blood platelet aggregation

Variable	Valsartan (V)		Valeryl 4-hydroxy valsartan (valeryl 4-hydroxy valsartan)	
Drug concentration	p-value vs. baseline		p-value vs. baseline	p-value V vs. valeryl 4- hydroxy valsartan

Whole blood impedance platelet aggregation induced by 1 mg/ml collagen
(ohms)

Baseline	29±7		29±7		
10 nM	30±8	NS	32±8	NS	NS
100 nM	30±7	NS	31±9	NS	NS
1 µM	27±7	NS	14±6	0.0001	0.0001
10 µM	29±6	NS	16±8	0.004	0.001
100 µM	20±8	0.02	17±8	0.01	NS

Cartridge-based Platelet Function Analysers (PFA-100™ and Ultegra®)

A consistent dose-dependent delay of the closure time (PFA) as a reduction of platelet aggregation units (Ultegra) was observed, indicating platelet inhibition under high shear conditions. Similar to the whole blood aggregation and epinephrine-induced aggregation, valeryl 4-hydroxy valsartan had stronger antiplatelet properties than valsartan. Table 3 demonstrates a representative experiment with cartridge-based analyzers.

Table 3. Cartridge-based analyzers

Variable	Valsartan (V)	Valeryl 4-hydroxy valsartan (valeryl 4-hydroxy valsartan)	
Drug concentration	p-value vs. baseline	p-value vs. baseline	p-value V vs. valeryl 4- hydroxy valsartan

PFA-100™ closure time (s) with the epinephrine/collagen cartridge *

Baseline	201±22		201±22		
10 nM	187±30	NS	179±28	NS	NS
100 nM	209±21	NS	190±24	NS	NS
1 µM	268±19	0.02	259±20	0.03	NS
10 µM	278±20	0.02	257±25	0.04	NS
100 µM	200±27	NS	232±31	NS	NS

Ultegra® (platelet activation units) Analyzer

Baseline	159±27		159±27		
10 nM	164±16	NS	177±23	NS	NS
100 nM	160±29	NS	181±31	NS	NS
1 µM	129±26	NS	134±29	NS	NS
10 µM	130±31	NS	119±38	NS	NS
100 µM	152±19	NS	168±35	NS	NS

Whole blood flow cytometry

Incubation with valsartan and valeryl 4-hydroxy valsartan slightly reduced the expression of GP IIb/IIIa (CD 41) and fibrinogen binding (PAC-1), and valeryl 4-hydroxy valsartan achieved this effect at therapeutic concentrations, whereas valsartan decreased expression of CD41 only at a high dose. Both agents significantly diminished concentration of P-selectin on platelet surface, and moderately reduced the expression of vitronectin receptors,

even this effect did not have statistical power to show difference between valsartan and valeryl 4-hydroxy valsartan. The incubation with valsartan and valeryl 4-hydroxy valsartan was not associated with any effect on PECAM-1 (CD31); GP Ib (CD42) and LAMP-2 (CD107b), PETA-3 (CD151), and platelet-leukocyte microparticles (CD151+14). The results of flow cytometry are presented on Table 4.

Table 4. Effect of Valsartan and valeryl 4-hydroxy valsartan on the expression of major platelet receptors

Variable	Valsartan (V)		Valeryl 4-hydroxy valsartan (valeryl 4-hydroxy valsartan)		
Drug concentration		p-value vs. baseline		p-value vs. baseline	p-value V vs. valeryl 4-hydroxy valsartan

Expression of platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31, log MFI)

Baseline	69.2±10.3		69.2±10.3		
10 nM	71.8±11.9	NS	74.2±13.4	NS	NS
100 nM	70.6±12.6	NS	69.7±15.1	NS	NS
1 µM	74.5±16.2	NS	70.3±16.4	NS	NS
10 µM	68.2±16.2	NS	73.1±9.3	NS	NS
100 µM	70.6±15.8	NS	71.2±15.5	NS	NS

Expression of platelet glycoprotein IIb/IIIa antigen (GPIIb, CD41, log MFI)

Baseline	521.8±98.2		521.8±98.2		
10 nM	531.2±102.5	NS	505.6±77.8	NS	NS
100 nM	502.9±112.7	NS	432.7±116.8	0.03	0.04
1 µM	498.2±94.5	NS	427.2±114.1	0.02	NS
10 µM	506.7±100.1	NS	515.9±156.2	NS	NS
100 µM	455.2±99.6	0.03	529.3±121.8	NS	0.04

Expression of glycoprotein Ib (GPIb, CD42b, log MFI)

Baseline	246.4±26.7		246.4±26.7		
10 nM	256.4±31.4	NS	236.4±18.7	NS	NS
100 nM	248.7±20.9	NS	267.9±39.4	NS	NS
1 µM	264.8±18.2	NS	255.5±24.8	NS	NS
10 µM	244.3±46.9	NS	249.7±41.8	NS	NS
100 µM	255.9±19.7	NS	248.1±19.5	NS	NS

Expression of platelet vitronectin receptor (CD51/CD61, log MFI)

Baseline	11.2±4.6		11.2±4.6		
10 nM	11.9±6.0	NS	12.1±4.2	NS	NS
100 nM	12.1±5.1	NS	8.5±3.1	0.02	0.01
1 µM	7.8±3.6	0.01	8.1±3.8	0.02	NS
10 µM	7.6±2.3	0.01	7.2±5.6	0.01	NS
100 µM	7.3±4.8	0.006	7.6±3.3	0.01	NS

Expression of P-selectin (CD 62p, % of cell positivity)

Baseline	9.1±3.8		9.1±3.8		
10 nM	9.8±2.7	NS	9.3±4.3	NS	NS
100 nM	10.3±4.1	NS	10.2±5.4	NS	NS
1 µM	7.2±3.2	0.03	7.3±3.7	0.03	NS
10 µM	7.2±3.6	0.03	6.9±4.2	0.03	NS
100 µM	7.8±4.2	NS	8.9±3.8	NS	NS

Expression of lysosome associated membrane protein -1 (LAMP-1, CD107a,

log MFI)

Baseline	8.7±3.2		8.7±3.2		
10 nM	9.1±3.8	NS	10.2±3.6	NS	NS
100 nM	8.9±2.7	NS	9.0±4.0	NS	NS
1 µM	9.4±3.9	NS	6.6±2.9	0.04	0.02
10 µM	6.5±3.2	0.04	5.8±3.2	0.03	NS
100 µM	10.1±4.5	NS	8.0±3.4	NS	NS

Expression of lysosome associated membrane protein -2 (LAMP-2, CD107b,

log MFI)

Baseline	6.6±2.1		6.6±2.1		
10 nM	7.6±3.2	NS	7.7±3.8	NS	NS
100 nM	7.0±2.7	NS	7.0±3.0	NS	NS
1 µM	6.8±3.5	NS	6.6±3.4	NS	NS
10 µM	7.1±3.3	NS	7.2±3.9	NS	NS
100 µM	7.2±3.8	NS	7.1±2.9	NS	NS

Expression of platelet/endothelial tetraspan antigen -3 (PETA-3, CD151, log

MFI)

Baseline	88.7±24.2		88.7±24.2		
10 nM	84.1±19.7	NS	89.4±18.2	NS	NS
100 nM	91.5±23.4	NS	92.7±22.2	NS	NS
1 µM	81.6±20.1	NS	90.5±15.7	NS	NS
10 µM	87.9±18.3	NS	84.2±31.1	NS	NS
100 µM	91.7±22.1	NS	93.4±27.4	NS	NS

Formation of platelet-leukocyte microparticles (CD151 + CD14, log MFI)

Baseline	92.2±19.3		92.2±19.3		
10 nM	91.2±20.5	NS	99.4±29.7	NS	NS
100 nM	88.4±21.9	NS	94.3±18.7	NS	NS
1 µM	93.5±23.8	NS	90.7±20.5	NS	NS
10 µM	96.5±18.7	NS	89.2±18.7	NS	NS
100 µM	90.5±19.2	NS	95.6±19.9	NS	NS

Glycoprotein IIb/IIIa activity (fibrinogen binding, PAC-1, log MFI)


Baseline	10.3±2.8		10.3±2.8		
10 nM	9.3±2.87	NS	11.0±4.5	NS	NS
100 nM	11.2±3.4	NS	9.0±3.3	NS	NS
1 µM	7.0±2.9	0.03	6.7±2.7	0.02	NS
10 µM	6.9±2.7	0.02	7.5±3.1	0.04	NS
100 µM	9.9±3.1	NS	9.9±3.0	NS	NS

The following examples illustrate the above-described invention; however, it is not intended to restrict the scope of this invention in any manner.

Example 1

Method of synthesis of valsartan metabolite

(S)-2-((4-Hydroxy-pentanoyl)-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]amino)-3-methyl-butyric acid




6.7 g (S)-3-Methyl-2-((4-oxo-pentanoyl)-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino)-butyric acid are dissolved in 60 ml methanol and cooled to 0°C. 2.25 g sodium borohydride are

added in small portions in order to keep the stirred reaction mixture below 27°C (strong foaming). The mixture is stirred at room temperature for 1 hour, concentrated in vacuo, dissolved in methylenechloride and extracted twice with 2N aqueous hydrochloric acid. The organic phase is dried, concentrated in vacuo and the product is received by chromatography (flash column, 240 g silicagel 60, KG40-62 micrometer, using a solvent mixture of methylenechloride, methanol, conc. aqueous ammonia (30:10:1 v/v). The fractions containing the product were concentrated, dissolved in methylenechloride and extracted with 2N aqueous hydrochloric acid and dried over sodium sulfate. After concentrating the residue is dried in vacuo (60°C) for 3 days yielding (S)-2-[(4-Hydroxy-pentanoyl)-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]amino]-3-methyl-butyric acid as a white foam ($[\alpha]_D^{20} = -58^\circ$ (c=1, methanol). TLC-Rf: 0.18 (toluene/ethylacetate/methylenechloride/formic acid 16:40:40:4).

The starting material (S)-3-Methyl-2-[(4-oxo-pentanoyl)-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino]-butyric acid can be prepared as follows:


(S)-2-[(2'-Cyano-biphenyl-4-ylmethyl)-[3-(2-methyl-[1,3]dioxolan-2-yl)-propionyl]-amino]-3-methyl-butyric acid benzyl ester



13.8 g (S)-2-[(2'-Cyano-biphenyl-4-ylmethyl)-amino]-3-methyl-butyric acid benzyl ester Hydrochloride (described in EP 443983) are dissolved in 50 ml methylenechloride, cooled to 0°C and treated with 23.8 ml ethyldiisopropylamine (Hünig base). To this mixture is added at 0°C a solution of 3-(2-Methyl-[1,3]dioxolan-2-yl)-propionyl chloride, prepared from 8.9 g 3-(2-Methyl-[1,3]dioxolan-2-yl)-propionic acid (Tetrahedron 37, 307, 1981) and 10.31 ml (1-Chloro-2-methyl-propenyl)-dimethyl-amine (Tetrahydron 54, 9207, 1998) in 40 ml methylenechloride. The reaction mixture is stirred at room temperature for 3-4 days, depending on the progress of the transformation. Preferably, 3-(2-Methyl-[1,3]dioxolan-2-yl)-propionyl chloride is added in 3-4


portions over 2 days. The reaction mixture is concentrated in vacuo, dissolved in ethylacetate, washed with water, 1N aqueous hydrochloric acid, water, dried over sodium sulfate and concentrated in vacuo. Flash column chromatography (240 g silicagel 60, 40-63 micrometer, petroleum ether/ethylacetate 2:1 to 1:1) provides, after drying of the product in vacuo at 50 °C, pure (S)-2-[(2'-Cyano-biphenyl-4-ylmethyl)-[3-(2-methyl-[1,3]dioxolan-2-yl)-propionyl]-amino]-3-methyl-butyrac acid benzyl ester as a golden, sticky residue. TLC-Rf: 0.23 (petroleum ether/ethylacetate 2:1).

(S)-2-[(2'-Cyano-biphenyl-4-ylmethyl)-(4-oxo-pentanoyl)-amino]-3-methyl-butyrac acid benzyl ester




9.8 g (S)-2-[(2'-Cyano-biphenyl-4-ylmethyl)-[3-(2-methyl-[1,3]dioxolan-2-yl)-propionyl]-amino]-3-methyl-butyrac acid benzyl ester are dissolved in 100 ml tetrahydrofurane and treated with 50 ml 1N aqueous hydrochloric acid. The mixture is stirred at room temperature for 6.5 hours, concentrated in vacuo and extracted with methylenechloride. The organic phase is washed with water, dried over sodium sulfate, concentrated in vacuo, evaporated and dried in vacuo at 50 °C for 1 hour. (S)-2-[(2'-Cyano-biphenyl-4-ylmethyl)-(4-oxo-pentanoyl)-amino]-3-methyl-butyrac acid benzyl ester is received as orange, viscous oil. THL-RF: 0.18 (petroleum ether/ethylacetate 2:1).

(S)-3-Methyl-2-[(4-oxo-pentanoyl)-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino]-butyric acid benzyl ester



8.64 g (S)-2-[(2'-Cyano-biphenyl-4-ylmethyl)-(4-oxo-pentanoyl)-amino]-3-methyl-butyrlic acid benzyl ester and 12.71 g Tributyltinazid (Aldrich) in 20 ml xylene are refluxed for 28 hours. The mixture is treated with 0.5N aqueous sodium hydroxide solution, the waterphase is washed with ether and ether phase is extracted once with water. The combined water phase is acidified with concentrated aqueous hydrochloric acid, extracted with methylenechloride, washed with water, suspended with active carbon, filtered, dried over sodium sulfate, concentrated and dried in vacuo. The product (S)-3-Methyl-2-[(4-oxo-pentanoyl)-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino]-butyric acid benzyl ester is received as brown foam. TLC-Rf: 0.36 (toluene/methylenechloride/methanol/formic acid 40:40:40:4).

(S)-3-Methyl-2-[(4-oxo-pentanoyl)-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino]-butyric acid



7.9 g (S)-3-Methyl-2-[(4-oxo-pentanoyl)-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino]-butyric acid benzyl ester in 160 ml tetrahydrofuran are hydrogenated under normal pressure at room temperature in the presence of 1.5 g palladium on carbon (10%) until saturation is achieved. The mixture is filtered and concentrated in vacuo providing (S)-3-Methyl-2-[(4-oxo-

pentanoyl)-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid as an almost white foam. TLC-Rf: 0.1 (toluene/methylenechloride/methanol/formic acid 40:40:40:4).

Although the present invention has been described in considerable detail with reference to certain preferred versions thereof, other versions are possible without departing from the spirit and scope of the preferred versions contained herein.

All publications and patents mentioned herein are incorporated by reference in their entirety as if set forth in full herein.

What is claimed is:

1. A method for inhibiting platelet aggregation comprising administering a therapeutically effective amount of an ARB or a pharmaceutically acceptable salt thereof, optionally in the presence of a pharmaceutically acceptable carrier, to a patient in need thereof.

2. The method of claim 1 wherein the ARB is valsartan.

3. A method of inhibiting platelet aggregation comprising administering a therapeutically effective amount of a metabolite of an ARB or a pharmaceutically acceptable salt thereof, optionally in the presence of a pharmaceutically acceptable carrier, to a patient in need thereof.

4. The method of claim 3 wherein the metabolite is valeryl 4-hydroxy valsartan.

5. A method of treating conditions mediated by platelet aggregation comprising administering a therapeutically effective amount of an ARB to a patient in need thereof.

6. The method of claim 5 wherein the ARB is valsartan.

7. The method of claim 5 wherein the condition mediated by platelet aggregation is acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion

8. A method of treating conditions mediated by platelet aggregation comprising administering a therapeutically effective amount of a metabolite of an ARB to a patient in need thereof.

9. The method of claim 8 wherein the metabolite is valeryl 4-hydroxy valsartan.

10. The method of claim 8 wherein the condition mediated by platelet aggregation is acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus,

11. peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion.

12. A pharmaceutical composition comprising a therapeutically effective amount of a metabolite of an ARB and a pharmaceutically acceptable carrier.

13. The pharmaceutical composition of claim 11 wherein the metabolite is valeryl 4-hydroxy valsartan.

14. Use of an ARB or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention, delay of progression or treatment of a disease and disorder mediated by platelet aggregation, in particular, acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion.

15. Use a metabolite of an ARB or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention, delay of progression or treatment of a disease and disorder mediated by platelet aggregation, in particular, acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/04997**A. CLASSIFICATION OF SUBJECT MATTER**
IPC 7 A61K31/41 A61P7/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data, PASCAL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MONTON MERCEDES ET AL: "Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation." JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, vol. 35, no. 6, June 2000 (2000-06), pages 906-913, XP009015828 ISSN: 0160-2446 abstract --- -/--	1-3,5-8, 10,14,15

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

21 August 2003

Date of mailing of the international search report

08/09/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Pacreu Largo, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/04997

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHLOPICKI S ET AL: "Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition." JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, vol. 51, no. 4 Part 1, December 2000 (2000-12), pages 715-722, XP002252057 ISSN: 0867-5910 abstract page 719 -page 721 ---	1-3,5-8, 10,14,15
X	BUCZKO W ET AL: "Studies on the antithrombotic action of AT1 receptor antagonists" MEDICAL SCIENCE MONITOR 2001 POLAND, vol. 7, no. 4, 2001, pages 600-605, XP002252058 ISSN: 1234-1010 abstract ---	1-3,5-8, 10,14,15
X	GUERRA-CUESTA JOSE I ET AL: "Effect of losartan on human platelet activation." JOURNAL OF HYPERTENSION, vol. 17, no. 3, March 1999 (1999-03), pages 447-452, XP009015995 ISSN: 0263-6352 abstract ---	1,3,5,7, 8,10,14, 15
X	WO 01 97805 A (NOVARTIS ERFIND VERWALT GMBH ;NOVARTIS AG (CH); GANTER SABINA MARI) 27 December 2001 (2001-12-27) page 7, paragraph 2 ---	5-7,14
X	EP 1 197 226 A (TAKEDA CHEMICAL INDUSTRIES LTD) 17 April 2002 (2002-04-17) page 5, line 41 - line 58 page 6, line 23 - line 28 ---	5-8,10, 14,15
X	WO 01 82858 A (SCHMIDT BORIS ;DREXLER HELMUT (DE); WALDEN MICHAEL (DE); FORSSMANN) 8 November 2001 (2001-11-08) page 3, paragraph 2 -page 4, paragraph 2 page 6; tables ---	1-3,5-8, 10,12, 14,15
X	BURNIER M M ET AL: "Angiotensin II receptor antagonists" LANCET, XX, XX, vol. 355, no. 9204, 19 February 2000 (2000-02-19), pages 637-645, XP004263093 ISSN: 0140-6736 the whole document --- -/--	5-8,10, 12,14,15

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/04997

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WALDMEIER F ET AL: "Pharmacokinetics, disposition and biotransformation of (14C)-radiolabelled valsartan in healthy male volunteers after a single oral dose." XENOBIOTICA, vol. 27, no. 1, 1997, pages 59-71, XP009015738 ISSN: 0049-8254 cited in the application page 68, paragraph 1	4,9
X	page 68, paragraph 1 ----	13
P,X	SEREBRUANY VICTOR L ET AL: "Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: A possible missing link to explain reduction of acute vascular events with angiotensin II receptor blockers." JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 41, no. 6 Supplement A, 19 March 2003 (2003-03-19), page 310A XP009015745 52nd Annual Scientific Session of the American College of Cardiology; Chicago, IL, USA; March 30-April 02, 2003 ISSN: 0735-1097 the whole document ----	1-15
P,X	KALINOWSKI LESZEK ET AL: "Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release." HYPERTENSION (BALTIMORE), vol. 40, no. 4, October 2002 (2002-10), pages 521-527, XP009015813 October, 2002 ISSN: 0194-911X the whole document -----	1-3,5-8, 10,14,15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/04997

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: —
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 1 to 10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box I.2

The subject-matter of present claims 1, 3, 5, 8, 12, 14, 15 and the dependent claims 7 and 10 is defined by means of the functional features:

ARB (angiotensin II receptor blocker),
metabolite of an ARB

Because of the character of the functional features, it cannot be guaranteed that the preformed search is complete.

It cannot be excluded that compounds fulfilling the requirements of the functional feature have not been identified as doing so in the prior art. If such compounds have not been identified in the application either, they have not been covered by the search.

The search has been carried out based on the functional feature per se, as well as the examples given in the description and claims 2 and 4.

It is further pointed out that the substantive examination can only be carried out to the same extent as the search.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/EP 03/04997

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0197805	A	27-12-2001	AU 8576801 A	02-01-2002
			BR 0111868 A	01-07-2003
			CA 2411882 A1	27-12-2001
			CZ 20024180 A3	16-04-2003
			WO 0197805 A2	27-12-2001
			EP 1296677 A2	02-04-2003
			NO 20026123 A	18-02-2003

EP 1197226	A	17-04-2002	AU 6019700 A	05-02-2001
			CA 2379666 A1	25-01-2001
			EP 1197226 A1	17-04-2002
			WO 0105428 A1	25-01-2001
			JP 2001089393 A	03-04-2001

WO 0182858	A	08-11-2001	AU 6740401 A	12-11-2001
			WO 0182858 A2	08-11-2001